Gauri Naik
Optra Systems Inc., USA
iPhronesis: A big data analytics platform for personalized & precision medicine
Biography: Gauri is a biotechnologist with an extensive commercial research and entrepreneurial background. Before founding Optra Systems, Inc., she was the founder and principal scientist at BioImagene Inc., a silicon valley based digital pathology company which was acquired by Roche Diagnostics. Gauri is responsible for enriching the domain knowledge of her companies, as well as involved in the strategic planning and business development activities. Gauri has extensive experience working in the genetics, cytology, microbiology, molecular biology, medical imaging and bioinformatics fields. Gauri was selected as a young scientist for various research programs in biotechnology and microbiology internationally. She has 11 U.S. patents published to her credit. She has published many research papers in international journals and has participated as a speaker in many international conferences. She is on the editorial and advisory boards of many prestigious journals and forums, including the Journal of Applied & Translational Genomics and the International Organization for Rare Genetic Disorders. Gauri was also awarded with the prestigious “Woman Entrepreneur Award" by the government of India.
Abstract: Healthcare and life sciences are generating BigData. Rising costs of healthcare has presented an opportunity for developing newer, robust healthcare models for efficient treatment, likelihood prediction such as patients presenting with vague symptoms, disease prevention by pre-clinical identification and personalized treatment options for patients. iPhronesis™ is an advanced BigData Analytics platform, built to address specific patient centric functions. iPhronesis™ delivers the true power of biomedical BigData by integrating disparate data sources such as EMR/ EHR/ genomics/ imaging/ scientific literature etc., both structured & unstructured, applying powerful analytics, some which are based on machine learning and Bio Natural Language Processing(Bio-NLP) tools enabling better understanding of data, discovering hidden relationships and presenting results with real evidences. iPhronesis™ allows users to choose from a series of domain specific workflows & processes, customizing each step, and integrating with custom algorithms. Every workflow is publishable as APIs or presented to the user interface. When data such as EMR/ EHR are combined with images or with genomics, it allows for generating patient longitudinal views, representing a complete patient/ cohort profile, identifying patterns, which help identify risk factors, predict disease progression, accurate disease classification and efficacy of treatment such as drug dose modification, adverse side effect identification and effects with comorbidity, to name a few. As a platform, iPhronesis™ also integrates with mobile applications increasing patient engagement, retention and enabling organizations to proactively reach a wider audience with analytics based evidences.
To read the full coverage, please click link:https://www.omicsonline.org/abstract/iphronesis-a-big-data-analytics-platform-for-personalized-precision-medicine/